Equities Analysts Set Expectations for RVPH FY2026 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Analysts at Zacks Research dropped their FY2026 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued to investors on Wednesday, April 1st. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings per share of ($2.21) for the year, down from their prior estimate of ($2.20). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ FY2027 earnings at ($1.74) EPS.

A number of other equities analysts also recently weighed in on RVPH. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, March 14th. Chardan Capital reissued a “buy” rating and issued a $40.00 price target on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Reviva Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Stock Down 11.1%

Shares of NASDAQ RVPH opened at $0.72 on Friday. Reviva Pharmaceuticals has a 12-month low of $0.59 and a 12-month high of $23.20. The firm’s 50-day simple moving average is $3.78 and its 200 day simple moving average is $7.68. The company has a market cap of $4.64 million, a price-to-earnings ratio of -0.08 and a beta of 0.64.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several large investors have recently bought and sold shares of RVPH. XTX Topco Ltd boosted its position in shares of Reviva Pharmaceuticals by 63.6% during the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after purchasing an additional 63,893 shares in the last quarter. State Street Corp increased its position in shares of Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after buying an additional 256,500 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals by 87.6% in the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after buying an additional 489,711 shares in the last quarter. Millennium Management LLC raised its stake in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares during the period. Finally, Lido Advisors LLC acquired a new stake in Reviva Pharmaceuticals during the 3rd quarter worth $37,000. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.